FGFR4 and TGF-β1 expression in hepatocellular carcinoma: Correlation with clinicopathological features and prognosis

International Journal of Medical Sciences

Volumn 10, Issue 12, 2013, Pages 1868-1875

  Chen, Zhixin ^a   Xie, Bao ^a,b   Zhu, Qinhua ^a   Xia, Qinghai ^a   Jiang, Songmin ^c   Cao, Ruoyu ^d   Shi, Lihua ^a   Qi, Dansi ^b   Li, Xiaokun ^a   Cai, Lin ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c THE THIRD AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^d CANGZHOU CENTRAL HOSPITAL   (China)

Author keywords

FGFR4; Hepatocellular carcinoma; Immunohistochemistry; Prognosis; TGF 1

Indexed keywords

ALPHA FETOPROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL CARCINOMA; LIVER SURGERY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PROGNOSIS; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR VOLUME;

FGFR4; HEPATOCELLULAR CARCINOMA; IMMUNOHISTOCHEMISTRY; PROGNOSIS.; TGF-Β1;

CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84887686733     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.6868     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
2. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int. 2008; 7: 237-257.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005; 42: 1208-1236.
4. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132: 2557-2576.
5. Chen YJ, Yeh SH, Chen JT, Wu CC, Hsu MT, Tsai SF, et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology. 2000; 119: 431-440.
6. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepato-cellular carcinoma after hepatectomy. Hepatol. 2003; 38: 200-207.
7. Caulín C, Scholl FG, Frontelo P, Gamallo C, Quintanilla M. Chronic exposure of cultured transformed mouse epidermal cells to transforming growth factor-beta 1 induces an epithelialmesenchymal trans differentiation and a spindle tumoral phenotype. Cell Growth Differ. 1995; 6: 1027-1035.
8. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, et al. TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell. 1996; 86: 531-542.
9. Portella G, Cumming SA, Liddell J, Cui W, Ireland H, Akhurst RJ, et al. Transforming growth factor beta is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion. Cell Growth Differ. 1998; 9: 393-404
10. Frontelo P, González-Garrigues M, Vilaró S, Gamallo C, Fabra A, Quintanilla M. Transforming growth factor beta 1 induces squamous carcinoma cell variants with increased metastatic abilities and a disorganized cytoskeleton. Exp Cell Res. 1998; 244: 420-432.
11. Romero D, Iglesias M, Vary CP, Quintanilla M. Functional blockade of Smad4 leads to a decrease in beta-catenin levels and signaling activity in human pancreatic carcinoma cells. Carcinogenesis. 2008; 29: 1070-1076.
12. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. Biol Chem. 2007; 282: 23337-23347.
13. Streit S, Mestel D, Schmidt M, Ullrich A, Berking C. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer. 2006; 94: 1879-1886.
14. Roidl A, Berger H, Kumar S, Bange J, Knyazev P, Ullrich A. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res. 2009; 15: 2058-2066.
15. Takahashi A, Sasaki H, Kim SJ, Kakizoe T, Miyao N, Suqimura T, et al. Identification of receptor genes in renal cell carcinoma associated with angiogenesis by differential hybridization technique. Biochem Biophys Res Commun. 1999; 257: 855-859.
16. Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alp ha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. Hepatol. 2009; 50: 118-127.
17. Kan M, Wu X, Wang F, McKeehan WL. Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. Biol Chem. 1999; 274: 15947-15952.
18. Lin BC, Wang M, Blackmore C, Desnoyers LR Liver-specific activities of FGF19 require Klotho beta. Biol Chem. 2007; 282: 27277-27284
19. Furukawa T. Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside. Gastroenterol. 2008; 43: 905-911.
20. Van Diest PJ, van Dam P, Henzen-Logmans SC, Berns E, van der Burg ME, Green J, et al. A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. J Clin Pathol. 1997; 50: 801-804
21. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, et al. The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer. 1999; 86: 1455-1462.
22. Motoda N, Matsuda Y, Onda M, Ishiwata T, Uchida E, Naito Z. Over expression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Int J Oncol. 2011; 38: 133-143.
23. Ueno T, Hashimoto O, Kimura R, Torimura T, Kawaguchi T, Nakamura T, et al. Relation of type II transforming growth factor-beta receptor to hepatic fibrosis and hepatocellular carcinoma. Int J Oncol. 2001; 18: 49-55.
24. Zhang L, Yuan SZ. Expression of c-erbB-2 oncogene protein, epidermal growth factor receptor, and TGFbeta1 in human pancreatic ductal adenocarcinoma. Hepatobiliary Pancreat Dis Int. 2002; 1: 620-623.
25. Masuhara M, Yasunaga M, Tanigawa K, Tamura F, Yamashita S, Sakaida I, et al. Expression of hepatocyte growth factor, transforming growth factor alpha, and transforming growth factor beta 1 messenger RNA in various human liver diseases and correlation with hepatocyte proliferation. Hepatodlogy. 1996; 24: 323-329.
26. Fan G, Ma X, Kren BT, Steer CJ. The retinoblastoma gene product inhibits TGF-beta1 induced apoptosis in primary rat hepatocytes and human HuH-7 hepatoma cells. Oncogene. 1996; 12:1909-1919.
27. Zong L, Qu Y, Xu MY, Dong YW, Lu LG. 18α-glycyrrhetinic acid down-regulates expression of type I and III collagen via TGF-B1/Smad signaling pathway in human and rat hepatic stellate cells. Int J Med Sci. 2012; 9: 370-379.
28. Li X, Zhang YY, Wang Q, Fu SB. Association between endogenous gene expression and growth regulation induced by TGF-beta1 in human gastric cancer cells. World J Gastroenterol. 2005; 11:61-68.
29. Lu Y, Wu LQ, Li CS, Wang SG, Han B. Expression of transforming growth factors in hepatocellular carcinoma and its relations with clinicopathological parameters and prognosis. Hepatobiliary Pancreat Dis Int. 2008; 7:174-178.
30. Eswarakumar V, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005; 16: 139-149.
31. Xie MH, Holcomb I, Deuel B, Dowd P, Huang A, Vaqts A, et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine. 1999; 11: 729-735.
32. Miura S, Mitsuhashi N, Shimizu H, Kimura F, Yoshidome H, Otsuka M, et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC cancer. 2012; 12:56.
33. Huang X, Yang C, Jin C, Luo Y, Wang F, McKeehan WL. Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis. Mol Carcinog. 2009; 48: 553-562.
34. Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD. Kinase switching in mesen-chymal-like non-small lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis. 2008; 25:834-854